Literature DB >> 3555382

[Trial of prevention of coronary aneurysm in Kawasaki's disease using plasma exchange or infusion of immunoglobulins].

E Villain, J Kachaner, D Sidi, G Blaysat, J F Piéchaud, E Pedroni.   

Abstract

Coronary aneurysms are present in 15-25% of cases of Kawasaki disease and are responsible for the morbidity and rapid mortality in this disease. We treated 20 children aged 20 +/- 16 months, less than 15 days (8 +/- 3.2) after onset of the disease, either by plasma exchange (7 exchange transfusions and one plasmapheresis) or by high dose intravenous gammaglobulins. No coronary anomalies or cardiac dysfunction prior to or after therapy (mean follow-up 8.3 +/- 4 months) was found. Tolerance to therapy was good and the course of the disease was arrested by exchange transfusions or shortened by gammaglobulin infusion. We conclude as have the Japanese, that this therapy is efficacious and safe, and should be initiated early.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3555382

Source DB:  PubMed          Journal:  Arch Fr Pediatr        ISSN: 0003-9764


  4 in total

Review 1.  Update on the treatment of Kawasaki disease in childhood.

Authors:  Robert P Sundel
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

2.  Kawasaki Disease.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-06

3.  Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease.

Authors:  Kei Takahashi; Toshiaki Oharaseki; Tomokazu Nagao; Yuki Yokouchi; Hitomi Yamada; Noriko Nagi-Miura; Naohito Ohno; Tsutomu Saji; Tomio Okazaki; Kazuo Suzuki
Journal:  Pediatr Rheumatol Online J       Date:  2011-09-29       Impact factor: 3.054

4.  A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?

Authors:  Wei Li; Xiufang He; Li Zhang; Zhouping Wang; Yanfei Wang; Huimei Lin; Jia Yuan; Xiaofei Xie; Youzhen Qin; Ping Huang
Journal:  Cardiovasc Ther       Date:  2021-06-18       Impact factor: 3.023

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.